News    Sports    Entertainment
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Sunday, March 21, 2010 1:42 PM

MacDougall Biomedical Communications

Image
Type: Company
Name: MacDougall Biomedical Communications

Quotes

"IMO-2125, an Agonist of TLR9 that Induces Endogenous IFN-a, Upregulates Broader Range of Gene Expression Profiles Compared to Exogenously Added IFN -a in Human PBMCs" ; Friday, April 16, 2010
Charles Nicolette, Ph D , Chief Scientific Officer and Vice President of ResearchResearch and DevelopmentDevelopment of Argos Therapeutics, added, "We are excited about the Arcelis immunotherapy platform because it is so well suited to the pathology of HIV infection; it overcomes the viral variability and the immune suppressive mechanisms that allow the virus to persist chronically and, remarkably, this is achieved without activation of CD4+ T cells, which are known to serve as factories for viral replication. This current study confirms previous proof-of-concept studies that have shown that our approach is able to induce a diverse immune response to HIV in patients."

More Content

All (3) | News (3) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0)
sort by: Date | Relevance
Idera Pharmaceuticals Announces Acceptance of I... [FinanzNachrichten.de - Mar 17 2010]
Argos Therapeutics Publishes Positive Immune Re... [AEGIS - Mar 06 2010]
Idera Pharmaceuticals Presents Mechanism of Act... [FinanzNachrichten.de - Feb 23 2010]
1
How To Use
Silobreaker
RSS
API
Widgets
Advertise With Us
Advertise


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2009 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.